These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25769229)

  • 1. Development of next generation of therapeutic IFN-α2b via genetic code expansion.
    Zhang B; Xu H; Chen J; Zheng Y; Wu Y; Si L; Wu L; Zhang C; Xia G; Zhang L; Zhou D
    Acta Biomater; 2015 Jun; 19():100-11. PubMed ID: 25769229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b.
    Imada T; Moriya K; Uchiyama M; Inukai N; Hitotsuyanagi M; Masuda A; Suzuki T; Ayukawa S; Tagawa YI; Dohmae N; Kohara M; Yamamura M; Kiga D
    ACS Synth Biol; 2018 Nov; 7(11):2537-2546. PubMed ID: 30277749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
    Ramon J; Saez V; Baez R; Aldana R; Hardy E
    Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
    Shahzadi SK; Qadir MA; Mahmood N; Ahmed M
    Protein Pept Lett; 2020; 27(3):219-224. PubMed ID: 31612813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
    Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
    J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.
    Chang CH; Rossi EA; Cardillo TM; Nordstrom DL; McBride WJ; Goldenberg DM
    Bioconjug Chem; 2009 Oct; 20(10):1899-907. PubMed ID: 19736932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
    J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pegylation on self-association of IFN-α2b.
    Mohs A; Ambrogelly A; Yang X; Haverick M; Cheung JK; Narasimhan C; Shameem M
    Mol Pharm; 2014 Jan; 11(1):158-63. PubMed ID: 24266549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone.
    Wu L; Chen J; Wu Y; Zhang B; Cai X; Zhang Z; Wang Y; Si L; Xu H; Zheng Y; Zhang C; Liang C; Li J; Zhang L; Zhang Q; Zhou D
    J Control Release; 2017 Mar; 249():84-93. PubMed ID: 28131652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
    Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
    Agarwala SS
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
    Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.